Vanishing of cohomology and parameter rigidity of actions of solvable Lie groups

We give a sufficient condition for parameter rigidity of actions of solvable Lie groups, by vanishing of (uncountably many) first cohomologies of the orbit foliations. In some cases, we can prove that vanishing of finitely many cohomologies is sufficient. For this purpose we use a rigidity property of quasiisometry. As an application we prove some actions of 2-step solvable Lie groups on mapping tori are parameter rigid. Special cases of these actions are considered in a paper of Matsumoto and Mitsumatsu. We also remark on the relation between transitive locally free actions of solvable Lie groups and lattices in solvable Lie groups, and apply results in rigidity theory of lattices in solvable Lie groups to construct transitive locally free actions with some properties.Comment: 35 pages, no figure

L-Mesitran® in the management of canine otitis externa

Dissertação de Mestrado Integrado em Medicina VeterináriaAt a time when antimicrobial resistance is rising steadily and the involved microorganisms are demonstrating zoonotic potential, honey and its derived products may prove useful in this ongoing battle. Otitis externa in dogs is considered to be one of the most prominent causes for presentation at veterinary practice. Some of the regularly administered agents in otitis treatments are no longer effective, as resistance has increased, perhaps due to the often long-term periods which are necessary for resolution and the accompanying tendency towards chronicity. In order to address the need for efficient alternative treatments, LMesitran ® Soft, a medical grade honey gel was used to treat 15 dogs with otitis externa of bacterial and/or fungal involvement. Success was based on clinical score decrease, cytology and owner input over time and with basis on culture results. 70% of enrolled dogs achieved clinical cure between days 7 to 14 and over 90% on day 21, the maximum established time limit, with a confidence interval of 95%. Furthermore, by day 7, 20% of dogs had obtained both clinical and cytological cures. This study was successfully able to demonstrate that the use of L-Mesitran® was effective in managing otitis externa in dogs, including cases in which highly resistant pathogens were present, such as methicillinresistant Staphylococcus pseudintermedius (MRSP), thus paving the way to future studies.ABSTRACT - L-MESITRAN® NO MANEIO DE OTITE EXTERNA CANINA – UM ESTUDO PILOTO - Numa altura em que nos deparamos com um aumento de bactérias com resistências aos antibióticos e em que os organismos envolvidos apresentam por vezes inclusivamente potencial zoonótico, o recurso ao mel e seus derivados pode ser uma inestimável ferramenta no decurso desta batalha. A otite externa em cães é um estímulo iatrotrópico frequente e das principais causas de idas ao médico veterinário. Alguns dos tratamentos habitualmente utilizados deixaram de ser eficazes à medida que as resistências surgiram, talvez consequência de terapêuticas prolongadas e recorrentes. Neste estudo avaliou-se uma potencial alternativa à terapêutica, recorrendo-se ao L-Mesitran® Soft, uma pomada contendo mel de grau clínico, para tratar 15 cães com otite externa de envolvimento bacteriano e/ou fúngico. A resposta foi considerada positiva de acordo com a diminuição da pontuação clínica, citologia e opinião dos donos, no decorrer do tempo. Estabelecido o limite de 21 dias, 70% dos cães tratados obteve cura clínica entre os dias 7 e 14 e mais de 90% no dia 21, com um intervalo de confiança de 95%. Ainda, até ao dia 7, 20% dos cães havia obtido cura clínica e citológica. Este estudo demonstrou que o L-Mesitran® foi eficaz no maneio dos casos de otite externa, incluindo aqueles em que estavam presentes bactérias com várias resistências aos antibióticos, como é o caso do Staphylococcus pseudintermedius com resistência à meticilina (SPRM), abrindo assim caminho para futuros estudos

Tail index estimation: a study on the evolution of heavy tails of regional bank indices and its impact on value-at-risk

This study peruses the leptokurtic evolution of regional banking indices belonging to the Americas, Asia, Australasia and Europe from 1973-2016 as measured by the tail index in order to assess the impact of tail index variation on VaR. Breaks in are detected under the testing framework proposed by Quintos et al. (2001) combined with both the originally suggested Hill estimator and, as an innovation, the newly proposed rank-size statistic. It was concluded that changes in led to material differences in VaR and the new test statistic showed superior statistical power over the Hill statistic

固有値分解とテンソル分解を用いた大規模グラフデータ分析に関する研究

筑波大学 (University of Tsukuba)201

K.－O. アーペルの討議倫理学に関する教育学的研究

広島大学(Hiroshima University)博士(教育学)Doctor of Philosophy in Educationdoctora

Inhibitory mechanisms of LAG-3–dependent T cell suppression

T cell activation is tightly regulated by both stimulatory and inhibitory co-receptors and has been a focus in the development of interventions for managing cancer or autoimmune diseases. Targeting the inhibitory co-receptors programmed cell death 1 (PD-1) and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) has successfully eradicated tumors but induced immune-related adverse events in humans and mice. The beneficial and adverse effects of targeting these co-receptors highlight their importance in cancer immunity and also autoimmunity. Although the therapeutic potencies of other inhibitory co-receptors are under extensive investigation, their inhibitory mechanisms and their functional differences are not well understood. Here we analyzed the inhibitory mechanisms of lymphocyte activation gene-3 (LAG-3), another inhibitory co-receptor, by using an in vitro T cell activation system and a high-affinity anti-LAG-3 antibody that strongly interferes with the binding of LAG-3 to its ligand. We found that the expression level of LAG-3 strongly correlates with the inhibitory function of LAG-3, suggesting that LAG-3 functions as a rheostat rather than as a breaker of T cell activation. By evaluating the inhibitory capacities of various LAG-3 variants relative to their expression levels, we found that LAG-3 transduces two independent inhibitory signals through an FXXL motif in the membrane-proximal region and the C-terminal EX repeat. These motifs have not been reported previously for inhibitory co-receptors, suggesting that LAG-3 inhibits T cell activation through a nonredundant inhibitory mechanisms along with the other inhibitory co-receptors. Our findings provide a rationale for combinatorial targeting of LAG-3 and the other inhibitory co-receptors to improve cancer immunotherapy